NEW YORK, June 19, 2017 /PRNewswire/ -- Schrödinger Inc., a privately-held company dedicated to revolutionizing drug discoverythrough advanced computational methods, today announced that Ramy Farid, President and Chief Executive Officer, will participate on a panel titled, "Software-Defined Science: Case Studies In Applied Data/Analytics" at the
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech companies Nimbus Therapeutics, Morphic Therapeutic, and Relay Therapeutics. Schrödinger's investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has over 300 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/schrodinger-to-participate-in-2nd-annual-cowen-and-company-futurehealth-conference-300475482.html
Subscribe to our Free Newsletters!
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...View All